Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2024 01:00 ET | Source: Vidac Pharma Holding PLC

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates

London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
March 12, 2024 02:30 ET | Source: Vidac Pharma Holding PLC

Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma

London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
August 03, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials

Los Angeles, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials Around 25+ key companies are developing Cutaneous T-Cell Lymphoma...
February 03, 2021 01:00 ET | Source: INNATE PHARMA

Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas

MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
April 02, 2019 16:04 ET | Source: Kura Oncology, Inc.

Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – –...
April 09, 2018 07:00 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)

La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
November 04, 2015 16:01 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update

MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
November 02, 2015 07:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata

MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase...